Collectively, these findings verify that the IL‐12 and nCD47‐SLAMF7 combination can effectively modulate the tumor‐suppressive microenvironment and significantly increase the infiltration of anti‐tumor effector T cells, consequently inhibiting glioma progression. The gene discussed is SLAMF7; the disease is central nervous system cancer.